Annual report
2503.TEDINET S100YT3M
Period2025-01-01 → 2025-12-31
Filed2026-08-03
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Amends S100XTVS. Amended by S100YTSJ (2026-08-03).
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.43T | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.34T | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥2.13T | 2023-01-01 → 2023-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.99T | 2022-01-01 → 2022-12-31v | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.82T | 2021-01-01 → 2021-12-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥209.7bn | 2025-01-01 → 2025-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥125.3bn | 2024-01-01 → 2024-12-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥237.9bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥139.7bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥197.0bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥191.4bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥99.6bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥147.5bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥58.2bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥112.7bn | 2023-01-01 → 2023-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥111.0bn | 2022-01-01 → 2022-12-31v | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥59.8bn | 2021-01-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥178.2bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥85.8bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥3.49T | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.35T | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥2.87T | at 2023-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.54T | at 2022-12-31v | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥2.47T | at 2021-12-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.90T | at 2025-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.82T | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.60T | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.53T | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.43T | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥1.29T | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.18T | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.13T | at 2023-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥980.0bn | at 2022-12-31v | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥894.2bn | at 2021-12-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥125.3bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥118.6bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥131.4bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥88.1bn | at 2022-12-31v | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥149.5bn | at 2021-12-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥295.4bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥242.8bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥203.2bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥135.6bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥219.3bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥185.0bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥329.4bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥226.1bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥10.4bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥56.4bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥110.5bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥58.1bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥35.9bn | 2023-01-01 → 2023-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥167.8bn | 2022-01-01 → 2022-12-31v | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥180.5bn | 2021-01-01 → 2021-12-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥182.13 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.87 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥139.16 | 2023-01-01 → 2023-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥135.08 | 2022-01-01 → 2022-12-31v | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥71.73 | 2021-01-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥182.13 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥71.86 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥139.15 | 2023-01-01 → 2023-12-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥135.07 | 2022-01-01 → 2022-12-31v | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥71.7 | 2021-01-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,588.59 | at 2025-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,458.68 | at 2024-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,398.47 | at 2023-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,210.16 | at 2022-12-31v | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,072.69 | at 2021-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 36.8% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 35.2% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 39.5% | at 2023-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 38.5% | at 2022-12-31v | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 36.2% | at 2021-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 12.0% | 2025-01-01 → 2025-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 5.0% | 2024-01-01 → 2024-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 10.7% | 2023-01-01 → 2023-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.8% | 2022-01-01 → 2022-12-31v | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.9% | 2021-01-01 → 2021-12-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 31,144 | at 2025-12-31 | Cons. | Number of employees |
| Revenue | ¥144.4bn | 2025-01-01 → 2025-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥194.6bn | 2024-01-01 → 2024-12-31 | Standalone | Operating revenue1 |
| Revenue | ¥139.0bn | 2023-01-01 → 2023-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥152.8bn | 2022-01-01 → 2022-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥139.5bn | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥56.0bn | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | ¥114.5bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | ¥48.1bn | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥60.4bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥62.2bn | 2023-01-01 → 2023-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥76.9bn | 2022-01-01 → 2022-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥73.8bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥47.9bn | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥332.2bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | ¥48.0bn | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | −¥344.9bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | ¥70.4bn | 2023-01-01 → 2023-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥48.7bn | 2022-01-01 → 2022-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥77.3bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.97T | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥1.85T | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥2.28T | at 2023-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.90T | at 2022-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.00T | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.42T | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥1.29T | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥551.3bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥561.9bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥964.2bn | at 2023-12-31v | Standalone | Net assets |
| Net assets / equity | ¥951.1bn | at 2022-12-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.01T | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥23.6bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥12.2bn | at 2024-12-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥59.28 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-425.84 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.91 | 2023-01-01 → 2023-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.24 | 2022-01-01 → 2022-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.67 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥74 | 2025-01-01 → 2025-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥71 | 2024-01-01 → 2024-12-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥71 | 2023-01-01 → 2023-12-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥69 | 2022-01-01 → 2022-12-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥65 | 2021-01-01 → 2021-12-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥680.54 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥693.7 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,190.61 | at 2023-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,174.47 | at 2022-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,208.06 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 28.0% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.4% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2023-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.1% | at 2022-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.6% | 2025-01-01 → 2025-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -45.2% | 2024-01-01 → 2024-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2023-01-01 → 2023-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.0% | 2022-01-01 → 2022-12-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-01-01 → 2021-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 914,000,000 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 914,000,000 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 914,000,000 | at 2023-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 914,000,000 | at 2022-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 914,000,000 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,124 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 1,067 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 977 | at 2023-12-31v | Standalone | Number of employees |
| Employees | 914 | at 2022-12-31v | Standalone | Number of employees |
| Employees | 1,156 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 75
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2025-01-01 → 2025-12-31 | ¥9.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-12-31 | 2200 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-12-31 | ¥101.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-12-31 | ¥32.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥69.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-12-31 | ¥417.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-12-31 | −¥1.1bn |
| Reconciling Itemsreconciling | capex | 2025-01-01 → 2025-12-31 | ¥10.0bn |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-12-31 | −¥79.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-12-31 | −¥79.4bn |
| Reconciling Itemsreconciling | segment assets | at 2025-12-31 | −¥542.4bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-12-31 | −¥63.6bn |
| Alcoholic Beveragesreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥50.5bn |
| Alcoholic Beveragesreportable segment | employees | at 2025-12-31 | 8800 pure |
| Alcoholic Beveragesreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥1.08T |
| Alcoholic Beveragesreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥1.08T |
| Alcoholic Beveragesreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥2.1bn |
| Alcoholic Beveragesreportable segment | segment assets | at 2025-12-31 | ¥1.43T |
| Alcoholic Beveragesreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥135.4bn |
| Health Sciencereportable segment | capex | 2025-01-01 → 2025-12-31 | ¥12.7bn |
| Health Sciencereportable segment | employees | at 2025-12-31 | 5643 pure |
| Health Sciencereportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥256.1bn |
| Health Sciencereportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥251.4bn |
| Health Sciencereportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥4.7bn |
| Health Sciencereportable segment | segment assets | at 2025-12-31 | ¥764.1bn |
| Health Sciencereportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥11.1bn |
| Non Alcoholic Beveragesreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥19.7bn |
| Non Alcoholic Beveragesreportable segment | employees | at 2025-12-31 | 7849 pure |
| Non Alcoholic Beveragesreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥581.5bn |
| Non Alcoholic Beveragesreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥578.2bn |
| Non Alcoholic Beveragesreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥3.3bn |
| Non Alcoholic Beveragesreportable segment | segment assets | at 2025-12-31 | ¥364.7bn |
| Non Alcoholic Beveragesreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥67.7bn |
| Pharmaceuticalsreportable segment | capex | 2025-01-01 → 2025-12-31 | ¥93.7bn |
| Pharmaceuticalsreportable segment | employees | at 2025-12-31 | 5161 pure |
| Pharmaceuticalsreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥496.8bn |
| Pharmaceuticalsreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥496.5bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2025-01-01 → 2025-12-31 | ¥312m |
| Pharmaceuticalsreportable segment | segment assets | at 2025-12-31 | ¥1.06T |
| Pharmaceuticalsreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥102.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-01-01 → 2024-12-31 | ¥7.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-12-31 | ¥97.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-12-31 | ¥21.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥76.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-12-31 | ¥362.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-12-31 | ¥30m |
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥10.4bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-12-31 | −¥86.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-12-31 | −¥86.4bn |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | −¥478.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥58.0bn |
| Alcoholic Beveragesreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥39.0bn |
| Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥1.08T |
| Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥1.08T |
| Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥2.3bn |
| Alcoholic Beveragesreportable segment | segment assets | at 2024-12-31 | ¥1.37T |
| Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥124.0bn |
| Health Sciencereportable segment | capex | 2024-01-01 → 2024-12-31 | ¥6.7bn |
| Health Sciencereportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥179.5bn |
| Health Sciencereportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥175.3bn |
| Health Sciencereportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥4.2bn |
| Health Sciencereportable segment | segment assets | at 2024-12-31 | ¥764.1bn |
| Health Sciencereportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥10.9bn |
| Non Alcoholic Beveragesreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥20.9bn |
| Non Alcoholic Beveragesreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥567.8bn |
| Non Alcoholic Beveragesreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥564.9bn |
| Non Alcoholic Beveragesreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥3.0bn |
| Non Alcoholic Beveragesreportable segment | segment assets | at 2024-12-31 | ¥326.4bn |
| Non Alcoholic Beveragesreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥64.0bn |
| Pharmaceuticalsreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥109.5bn |
| Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥495.6bn |
| Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥495.3bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-12-31 | ¥264m |
| Pharmaceuticalsreportable segment | segment assets | at 2024-12-31 | ¥1.01T |
| Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥91.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,405
| Item | Context | Value | Unit |
|---|---|---|---|
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row34Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row35Member | Original text (Japanese)㈱グルメ杵屋 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row35Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row35Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row36Member | Original text (Japanese)㈱中村屋 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row36Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row36Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row37Member | Original text (Japanese)㈱エスエルディー | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row37Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row37Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row38Member | Original text (Japanese)㈱バローホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row38Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row38Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row39Member | Original text (Japanese)イオン九州㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row39Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row39Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row40Member | Original text (Japanese)㈱ツルハホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row40Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row40Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row41Member | Original text (Japanese)㈱コスモス薬品 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row41Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row41Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row42Member | Original text (Japanese)カメイ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row42Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row42Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row43Member | Original text (Japanese)㈱リテールパートナーズ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row43Member | Original text (Japanese)営業政策等の取引関係を維持・強化するため保有しておりましたが、当事業年度に売却を実施しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row43Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row44Member | Original text (Japanese)ウエルシアホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row44Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row44Member | Original text (Japanese)無 | |
| Footnotes specified investment shares held for purposes other than pure investment largest holding company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment largest holding company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Unit of figures stated financial information | CurrentYearDuration | Original text (Japanese)(3) 連結財務諸表及び財務諸表は、百万円未満を四捨五入して記載しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated statement of financial position IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of profit or loss IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes reporting entity consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes basis of preparation consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes new standards not yet applied consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Information about geographical areas IFRS (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |